{{medical}}
{{Drugbox
| verifiedrevid = 462248688
| IUPAC_name = 3,7-dihydropurine-6-thione
| image = Mercaptopurine.svg

<!--Clinical data-->
| tradename = Purinethol
| Drugs.com = {{drugs.com|monograph|mercaptopurine}}
| MedlinePlus = a682653
| pregnancy_category = D
| legal_status = Rx-only
| routes_of_administration = 口服

<!--Pharmacokinetic data-->
| bioavailability = 5~37%
| metabolism = [[黄嘌呤氧化酶|黄嘌呤氧化酶]]
| elimination_half-life = 60至120分钟，活性代谢产物则更长
| excretion = [[肾脏|肾脏]]

<!--Identifiers-->
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 50-44-2
| ATC_prefix = L01
| ATC_suffix = BB02
| PubChem = 667490
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
 | DrugBank = DB01033
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 580869
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = PKK6MUZ20G
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D04931
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 50667
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1425

<!--Chemical data-->
| C=5 | H=4 | N=4 | S=1 
| molecular_weight = 152.177 g/mol
| smiles = S=C2/N=C\Nc1ncnc12
| InChI = 1/C5H4N4S/c10-5-3-4(7-1-6-3)8-2-9-5/h1-2H,(H2,6,7,8,9,10)
| InChIKey = GLVAUDGFNGKCSF-UHFFFAOYAL
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C5H4N4S/c10-5-3-4(7-1-6-3)8-2-9-5/h1-2H,(H2,6,7,8,9,10)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = GLVAUDGFNGKCSF-UHFFFAOYSA-N
}}

'''巯嘌呤'''（{{lang-en|'''Mercaptopurine'''}}，简称'''6-MP'''，又名'''6-巯基嘌呤'''、'''巯基嘌呤'''或'''巯唑嘌呤'''）是一种[[硫嘌呤类|硫嘌呤类]][[化疗|化疗]]药物和[[免疫抑制剂|免疫抑制剂]]。<ref name="pmid18506437">{{Cite journal | last1 = Sahasranaman | first1 = S. | last2 = Howard | first2 = D. | last3 = Roy | first3 = S. | doi = 10.1007/s00228-008-0478-6 | title = Clinical pharmacology and pharmacogenetics of thiopurines | journal = European Journal of Clinical Pharmacology | volume = 64 | issue = 8 | pages = 753–767 | year = 2008 | pmid =  18506437| pmc = }}</ref>

==历史==
1951年，[[格特鲁德·B·埃利恩|格特鲁德·B·埃利恩]]和[[喬治·H·希欽斯|喬治·H·希欽斯]]用[[干酪乳杆菌|干酪乳杆菌]]试验了100多种[[嘌呤类似物|嘌呤类似物]]，其中亦包括了巯嘌呤。<ref>{{Cite journal | last1 = Elion | first1 = G. B. | last2 = Burgi | first2 = E. | last3 = Hitchings | first3 = G. H. | journal = Journal of the American Chemical Society | title = Studies on Condensed Pyrimidine Systems. IX. The Synthesis of Some 6-Substituted Purines | volume = 74 | issue = 2 | pages = 411 | year = 1952 | doi = 10.1021/ja01122a037 | pmid =  | pmc = }}</ref> 他们发现，这种物质是很强的[[嘌呤|嘌呤]][[拮抗剂|拮抗剂]]，于是开始在[[小鼠|小鼠]]与[[白血病|白血病]]患者上进行[[临床试验|临床试验]]，并大获成功。<ref>{{Cite journal | last1 = Clarke | first1 = D. A. | last2 = Philips | first2 = F. S. | last3 = Sternberg | first3 = S. S. | last4 = Stock | first4 = C. C. | last5 = Elion | first5 = G. B. | last6 = Hitchings | first6 = G. H. | title = 6-Mercaptopurine: Effects in mouse sarcoma 180 and in normal animals | journal = Cancer research | volume = 13 | issue = 8 | pages = 593–604 | year = 1953 | pmid = 13082494 }}</ref><ref>{{Cite journal | last1 = Elion | first1 = G. B. | last2 = Singer | first2 = S. | last3 = Hitchings | first3 = G. H. | doi = 10.1111/j.1749-6632.1954.tb40009.x | title = Microbiological Effects of 6-Mercaptopurine | journal = Annals of the New York Academy of Sciences | volume = 60 | issue = 2 | pages = 200–206 | year = 1954 | pmid =  14350524| pmc = }}</ref> [[美国食品和药品管理局|美国食品和药品管理局]]（FDA）在1953年批准了巯嘌呤上市——此时巯嘌呤被合成出来仅两年时间，而临床试验更是只进行了十个月。

==用途==
巯嘌呤主要用于[[急性白血病|急性白血病]]（包括[[急性粒细胞白血病|急性粒细胞白血病]]和[[急性淋巴细胞白血病|急性淋巴细胞白血病]]）的维持治疗，<ref name="gale" /> 同时也被用于治疗恶性[[葡萄胎|葡萄胎]]、[[绒毛膜癌|绒毛膜上皮癌]]、<ref>{{Cite journal | last1 = Sung | first1 = H. C. | last2 = Wu | first2 = P. C. | last3 = Ho | first3 = T. H. | title = Treatment of Choriocarcinoma and Chorioadenoma Destruens with 6-Mercaptopurine and Surgery | journal = Acta - Unio Internationalis Contra Cancrum | volume = 20 | pages = 493–502 | year = 1964 | pmid = 14151970}}</ref> [[真红细胞增多症|真红细胞增多症]]、<ref>{{Cite journal | last1 = Shullenberger | first1 = C. C. | title = Long-rangetreatment of polycythemia vera with 6-mercaptopurine | journal = Cancer chemotherapy reports. Part 1 | volume = 16 | pages = 251–252 | year = 1962 | pmid = 13912387 }}</ref> [[银屑病关节炎|银屑病关节炎]]、<ref>{{Cite journal | last1 = Baum | first1 = J. | last2 = Hurd | first2 = E. | last3 = Lewis | first3 = D. | last4 = Ferguson | first4 = J. L. | last5 = Ziff | first5 = M. | title = Treatment of psoriatic arthritis with 6-mercaptopurine | doi = 10.1002/art.1780160202 | journal = Arthritis & Rheumatism | volume = 16 | issue = 2 | pages = 139 | year = 1973 | pmid =  | pmc = }}</ref> 和[[炎症性肠炎|炎症性肠炎]]（如[[克罗恩病|克罗恩病]]和[[溃疡性结肠炎|溃疡性结肠炎]]）。<ref name="pmid11683683">{{cite journal |author=Nielsen OH, Vainer B, Rask-Madsen J |title=Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine |journal=Aliment. Pharmacol. Ther. |volume=15 |issue=11 |pages=1699–708 |pmid=11683683 |doi=10.1046/j.1365-2036.2001.01102.x |url=http://www3.interscience.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0269-2813&date=2001&volume=15&issue=11&spage=1699 |date=November 2001 }}{{Dead link|date=2019年4月 |bot=InternetArchiveBot |fix-attempted=yes }}</ref>

有研究显示巯嘌呤在体外具有抗[[副结核分枝杆菌|副结核分枝杆菌]]（''Mycobacterium paratuberculosis''）的活性。<ref name="pmid18070971">{{cite journal |author=Shin SJ, Collins MT |title=Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro |journal=Antimicrob. Agents Chemother. |volume=52 |issue=2 |pages=418–26 |pmid=18070971 |pmc=2224720 |doi=10.1128/AAC.00678-07 |url=http://aac.asm.org/cgi/pmidlookup?view=long&pmid=18070971|date=February 2008}}</ref>

==作用机理==
巯嘌呤是一种嘌呤类似物，属于嘌呤拮抗剂类[[抗代谢物|抗代谢物]]。<ref name="gale" /> 它能够抑制酰胺转移酶，从而干扰嘌呤[[核苷酸|核苷酸]]合成；能够抑制[[次黄嘌呤|次黄嘌呤]]核苷酸转为[[腺嘌呤|腺嘌呤]]核苷酸及次黄嘌呤核苷酸转为[[黄嘌呤|黄嘌呤]]核苷酸、[[鸟嘌呤|鸟嘌呤]]核苷酸的过程；还能够抑制[[烟酰胺腺嘌呤二核苷酸|烟酰胺腺嘌呤二核苷酸]]（NAD+）的合成及引起[[脫氧腺苷三磷酸|脫氧腺苷三磷酸]]（dATP）和[[脫氧鸟苷三磷酸|脫氧鸟苷三磷酸]]（dGTP）水平的下降。这使得巯嘌呤能够有效抑制DNA的合成，从而抑制[[肿瘤|肿瘤]]细胞的生长。<ref name="pmid18506437" /><ref>{{Cite journal | last1 = Cara | first1 = C. J. | last2 = Pena | first2 = A. S. | last3 = Sans | first3 = M. | last4 = Rodrigo | first4 = L. | last5 = Guerrero-Esteo | first5 = M. | last6 = Hinojosa | first6 = J. | last7 = García-Paredes | first7 = J. | last8 = Guijarro | first8 = L. G. | title = Reviewing the mechanism of action of thiopurine drugs: Towards a new paradigm in clinical practice | journal = Medical science monitor : international medical journal of experimental and clinical research | volume = 10 | issue = 11 | pages = RA247–RA254 | year = 2004 | pmid = 15507865 }}</ref>

==不良反应==
巯嘌呤的[[不良反应|不良反应]]较多，且可能达到很严重的程度。

其中较轻的有[[腹泻|腹泻]]、[[恶心|恶心]]、[[呕吐|呕吐]]、[[食欲减退|食欲减退]]、[[疲倦|疲倦]]、过敏反应（如[[皮疹|皮疹]]和[[发痒|发痒]]）、[[脱发|脱发]]等；较严重的则有：[[骨髓抑制|骨髓抑制]]、[[发热|发热]]、[[咽喉痛|咽喉痛]]、[[口腔溃疡|口腔溃疡]]、[[出血|出血]]、[[黄疸|黄疸]]等；十分严重的（但较罕见）的有[[血尿|血尿]]、[[黑粪症|黑粪症]]、急性尿酸性肾病、致死性肝中毒等。<ref name="gale">{{Cite book|last=Thackery |first=Ellen |title=The Gale Encyclopedia of Cancer: L-Z |publisher=Thomson Gale |location=Detroit |year=2002 |page=685-687 |isbn=0-7876-5611-9}}</ref>

骨髓抑制是巯嘌呤最常见的副作用之一；患者最好每周进行一次[[全血细胞计数|全血细胞计数]]检查，并在发现无法解释的[[白细胞|白细胞]]或其他血细胞计数大幅度异常下降时停止用药。 

出现骨髓抑制的病人应检查是否缺乏[[硫嘌呤甲基转移酶|硫嘌呤甲基转移酶]]（TPMT）。TPMT在巯嘌呤和[[硫鸟嘌呤|硫鸟嘌呤]]等巯基嘌呤类药物的代谢中有着重要的作用——患有TPMT缺乏症的人（占总人口约300分之一）在使用这些药物的时候更容易出现严重甚至致命的骨髓抑制。<ref>{{Cite journal | last1 = Yates | first1 = C. R. | last2 = Krynetski | first2 = E. Y. | last3 = Loennechen | first3 = T. | last4 = Fessing | first4 = M. Y. | last5 = Tai | first5 = H. L. | last6 = Pui | first6 = C. H. | last7 = Relling | first7 = M. V. | last8 = Evans | first8 = W. E. | title = Molecular diagnosis of thiopurine S-methyltransferase deficiency: Genetic basis for azathioprine and mercaptopurine intolerance | journal = Annals of internal medicine | volume = 126 | issue = 8 | pages = 608–614 | year = 1997 | pmid = 9103127}}</ref> 对这类病人来说，若有必要则仍可继续使用巯嘌呤治疗，但必须使用一个较低的剂量。

==注意事项==
抗[[痛风|痛风]]药[[别嘌醇|别嘌醇]]能够抑制代谢巯嘌呤的[[黄嘌呤氧化酶|黄嘌呤氧化酶]]的活性，因此同时使用两药的的患者容易导致巯嘌呤中毒。在这种情况下应该减少巯嘌呤的剂量或停用巯嘌呤。不过最近有研究显示，利用这种药物相互作用在巯嘌呤治疗时适量使用别嘌醇能够显著提高巯嘌呤对炎症性肠病无应答者（即对治疗无反应）的疗效，并且相对于增加[[糖皮质激素|糖皮质激素]]用量的方法来说更加安全。<ref>{{Cite journal | last1 = Sparrow | first1 = M. P. | last2 = Hande | first2 = S. A. | last3 = Friedman | first3 = S. | last4 = Cao | first4 = D. | last5 = Hanauer | first5 = S. B. | title = Effect of Allopurinol on Clinical Outcomes in Inflammatory Bowel Disease Nonresponders to Azathioprine or 6-Mercaptopurine | doi = 10.1016/j.cgh.2006.11.020 | journal = Clinical Gastroenterology and Hepatology | volume = 5 | issue = 2 | pages = 209–214 | year = 2007 | pmid = 17296529 | pmc = }}</ref>

作为一种免疫抑制剂，巯嘌呤会减弱[[免疫系统|免疫系统]]抵抗[[感染|感染]]的能力。接受治疗的患者在接种[[疫苗|疫苗]]时必须经过主治医生批准，并且禁止注射活疫苗（如[[轮状病毒|轮状病毒]]疫苗、[[脊髓灰质炎|脊髓灰质炎]]疫苗）；最近注射疫苗的患者则应避免使用此药。<ref name="gale" />

一般来说，医生不推荐[[怀|怀]]孕时使用巯嘌呤，因为研究证实使用巯嘌呤（或类似的[[硫唑嘌呤|硫唑嘌呤]]）的[[孕妇|孕妇]]的胎儿异常率与[[流产|流产]]率分别是正常人的7倍和20倍。<ref name=mercaptopurine_birth_outcome>{{cite journal | first = B. | last = Nørgård | coauthors = L. Pedersen, K. Fonager, S. Rasmussen, H. Sørensen | title = Azathioprine, mercaptopurine and birth outcome: a population-based cohort study | journal = Alimentary pharmacology and therapeutics | volume = 17 | issue = 6 | pages = 827–834 | pmid = 12641505 | doi =10.1046/j.1365-2036.2003.01537.x|date=March 2003}}</ref> 但不同于有同样效果的[[甲氨蝶呤|甲氨蝶呤]]，巯嘌呤并不是一种有效的[[堕胎药|堕胎药]]；1999年的一项研究中所有使用它[[堕胎|堕胎]]的孕妇身上在两周之后都观察到了胎儿[[心脏|心脏]]活动，因而不得不进行[[吸引流产|吸引流产]]。<ref name=useless_in_abortion>{{cite journal | first = Anne R. | last = Davis | coauthors = Leslie Miller, Hisham Tamimi, and Allen Gown | title = Methotrexate Compared With Mercaptopurine for Early Induced Abortion | journal = Obstetrics & Gynecology | volume = 93 | issue = 6 | pages = 904–9 | pmid = 10362152 | url = http://www.greenjournal.org/cgi/content/full/93/6/904 | doi = 10.1016/S0029-7844(98)00569-9|date=June 1999}}</ref>

==致癌性==
巯嘌呤在动物和人类身上能够引起[[染色体|染色体]]变化，且有研究显示高剂量巯嘌呤与其它[[细胞毒|细胞毒]]药物合用会增加患上[[白血病|白血病]]的风险。<ref name=6mp_and_leukemia>{{cite journal |author=Bo J, Schrøder H, Kristinsson J, Madsen B, Szumlanski C, Weinshilboum R, Andersen JB, Schmiegelow K |title=Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism |journal=Cancer |volume=86 |issue=6 |pages=1080–6 |pmid=10491537|doi=10.1002/(SICI)1097-0142(19990915)86:6<1080::AID-CNCR26>3.0.CO;2-5|date=September 1999}}</ref> 不过科学家认为，对于巯嘌呤本身，尽管不能排除[[致癌性|致癌性]]的可能，这种可能性总体来说是很小的；<ref name=6mp_in_mice>{{cite journal | first = A. | last = Maekawa | coauthors = T. Nagaoka, H. Onodera, Y. Matsushima, A. Todate, M. Shibutani, H. Ogasawara, Y. Kodama and Y. Hayashi | title = Two-year carcinogenicity study of 6-mercaptopurine in F344 rats | journal = Journal of Cancer Research and Clinical Oncology | volume = 116 | issue = 3 | pages = 245–250 | pmid = 2370249 | url = http://www.springerlink.com/content/k28hxj615p761764/ | doi = 10.1007/BF01612898|date=May 1990}}</ref> [[国际癌症研究机构|国际癌症研究机构]]（IARC）也仅将其列为第三类物质（尚不能确定其是否对人体致癌）。

==合成==
[[File:Mercaptopurine_synthesis.png|thumb]]

==另见==
*[[硫唑嘌呤|硫唑嘌呤]]

==参考资料==
{{Reflist|2}}

{{化疗药物}}

[[Category:抗肿瘤抗代谢物|Category:抗肿瘤抗代谢物]]
[[Category:嘌呤|Category:嘌呤]]